MARVELD3 and pancreatic neoplasm: In line with these findings, MarvelD3, a dynamic regulator of the MEKK1–c-Jun NH2-terminal kinase (JNK) pathway, was described to reduce pancreatic cancer cells’ tumor formation in vivo and Caco-2 cells’ proliferation and migration.